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Endoplasmic Reticulum Stress Is Associated With Autophagy and
Cardiomyocyte Remodeling in Experimental and Human Atrial
Fibrillation
Marit Wiersma, PhD;* Roelien A. M. Meijering, PhD;* Xiao-Yan Qi, PhD; Deli Zhang, PhD; Tao Liu, MD; Femke Hoogstra-Berends, BSc;
Ody C. M. Sibon, PhD; Robert H. Henning, MD, PhD; Stanley Nattel, MD; Bianca J. J. M. Brundel, PhD
Background-—Derailment of proteostasis, the homeostasis of production, function, and breakdown of proteins, contributes
importantly to the self-perpetuating nature of atrial ﬁbrillation (AF), the most common heart rhythm disorder in humans. Autophagy
plays an important role in proteostasis by degrading aberrant proteins and organelles. Herein, we investigated the role of
autophagy and its activation pathway in experimental and clinical AF.
Methods and Results-—Tachypacing of HL-1 atrial cardiomyocytes causes a gradual and signiﬁcant activation of autophagy, as
evidenced by enhanced LC3B-II expression, autophagic ﬂux and autophagosome formation, and degradation of p62, resulting in
reduction of Ca2+ amplitude. Autophagy is activated downstream of endoplasmic reticulum (ER) stress: blocking ER stress by the
chemical chaperone 4-phenyl butyrate, overexpression of the ER chaperone-protein heat shock protein A5, or overexpression of a
phosphorylation-blocked mutant of eukaryotic initiation factor 2a (eIF2a) prevents autophagy activation and Ca2+-transient loss in
tachypaced HL-1 cardiomyocytes. Moreover, pharmacological inhibition of ER stress in tachypaced Drosophila conﬁrms its role in
derailing cardiomyocyte function. In vivo treatment with sodium salt of phenyl butyrate protected atrial-tachypaced dog
cardiomyocytes from electrical remodeling (action potential duration shortening, L-type Ca2+-current reduction), cellular Ca2+-
handling/contractile dysfunction, and ER stress and autophagy; it also attenuated AF progression. Finally, atrial tissue from patients
with persistent AF reveals activation of autophagy and induction of ER stress, which correlates with markers of cardiomyocyte damage.
Conclusions-—These results identify ER stress–associated autophagy as an important pathway in AF progression and demonstrate
the potential therapeutic action of the ER-stress inhibitor 4-phenyl butyrate. ( J Am Heart Assoc. 2017;6:e006458. DOI: 10.
1161/JAHA.117.006458.)
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• molecular biology • structural biology • tachypacing
A trial ﬁbrillation (AF) is the most common persistentclinical tachyarrhythmia.1 Many patients experience clin-
ical symptoms, including palpitations, fatigue, and weakness; AF
also puts patients at risk for cardiac morbidity and mortality and
often necessitates life-long anticoagulant therapy.1 When AF
persists, sinus rhythm (SR) reversion and maintenance becomes
progressively more difﬁcult. Central to this self-perpetuating
nature of AF is the remodeling of cardiomyocytes as a
consequence of the increased atrial activation rate, resulting in
disturbances of electrophysiological features and contraction
and structural damage.2 Therapeutic strategies that limit
cardiomyocyte remodeling would improve the success of
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cardioversion, but are unavailable.1 To identify druggable targets,
recent research is increasingly directed at uncovering the
molecular mechanisms underlying atrial remodeling.
Derailment of proteostasis (ie, the homeostasis of protein
production, function, and breakdown) contributes to cardiomy-
ocyte remodeling and predisposes to AF in experimentalmodels
and patients with AF.3–6 Among recently identiﬁed factors
contributing to proteostasis derailment in AF is the activation of
proteases that degrade contractile and structural proteins,
including cardiac troponins and a-tubulin, resulting in break-
down of the microtubule network and cardiomyocyte structural
remodeling.3,4,7 The importance of proper proteostasis is also
revealed by the attenuation of cardiomyocyte remodeling and
dysfunction as a consequence of induction of heat shock
proteins (HSPs), whose chaperone function subserves correct
folding and preservation of contractile proteins.8,9
Macroautophagy (hereafter “autophagy”) is critically
involved in maintaining proteostasis.10 Autophagy is an evolu-
tionarily conserved protein-degradation pathway that removes
damaged or expired proteins and organelles by sequestration in
autophagosomes and subsequent lysosomal degradation.10,11
Recent work shows that the mammalian target of rapamycin
(mTOR) pathway12,13 and endoplasmic reticulum (ER) stress
response13,14 can activate the autophagy-lysosome pathway,
which plays a major role in the cardiac stress response.15
Autophagy is widely involved as a cell-stress pathway, whose
excessive activation triggers cardiac remodeling in response to
degradation of essential proteins and organelles. Activation of
autophagy in the heart is implicated in cardiac remodeling in
mitral regurgitation16,17 and cardiac hypertrophy.18,19
Herein, we report that activation of autophagy by upstream
ER stress constitutes an important mechanism of cardiac
remodeling in tachypaced atrial-derived cardiomyocytes, Dro-
sophila, and dogs and in atrial biopsy specimens from patients
with AF. We provide data to show that blocking ER stress, by the
chemical chaperone 4-phenyl butyrate (4PBA), overexpression
of the ER chaperone HSPA5, or mutant constructs of eIF2a,
inhibits activation of autophagy and thereby precludes electri-
cal and contractile dysfunction in both in vitro and in vivo AF
models. Thus, our study points to ER stress as a potential novel
druggable target to attenuate cardiac remodeling in AF.
Methods
HL-1 Atrial Cardiomyocyte Cell Culture,
Transfections, and Constructs
HL-1 atrial cardiomyocytes derived from adult mouse atria were
obtained from Dr William Claycomb (Louisiana State University,
New Orleans).20 The cardiomyocytes were maintained in
complete Claycomb Medium (Sigma) supplemented with 10%
fetal bovine serum, 100 U/mL penicillin, 100 lg/mL strepto-
mycin, 4 mmol/L L-glutamine, 0.3 mmol/L L-ascorbic acid, and
100 lmol/L norepinephrine. HL-1 cardiomyocytes were cul-
tured on cell culture plastics or on glass coverslips coated with
0.02% gelatin in a humidiﬁed atmosphere of 5% CO2 at 37°C.
Where indicated, HL-1 cardiomyocytes were transiently trans-
fected with the LC3B–green ﬂuorescent protein (kind gift of
Professor T. Johansen),21 HSPA5 (kind gift of Professor H.
Kampinga), pcDNA3.1+ (empty), eIF2a wild type, eIF2a S51A, or
eIF2a S51D plasmid, by the use of Lipofectamine 2000.
Tachypacing of HL-1 Cardiomyocytes and
Calcium Transient Measurements
HL-1 cardiomyocytes were subjected to tachypacing, as
described before.3 In short, HL-1 cardiomyocytes were
subjected to 1 Hz (normal pacing) or 6 Hz (tachypacing;
Table 1), 40 V, and 20-millisecond pulses, for a maximal
duration of 8 hours via the C-Pace EP Culture Stimulator.
These frequencies were used to standardize the control ﬁring
frequency (1 Hz is the average spontaneous beating rate of
HL-1 cardiomyocytes) and to produce a similar frequency
increment with tachypacing (6-fold increase) to that which
occurs during AF in humans. To measure Ca2+ transients
(CaTs), HL-1 cardiomyocytes were incubated for 30 minutes
with 2 lmol/L Ca2+-sensitive dye, Fluo-4-AM. Fluo-4–loaded
cardiomyocytes were excited by a 488-nm laser with emission
at 500 to 550 nm and were visually recorded with a
409objective, using a Solamere-Nipkow-Confocal-Live-Cell-
Imaging system (based on a DM IRE2 inverted microscope).
The live recording of CaT in HL-1 cardiomyocytes was
Clinical Perspective
What Is New?
• Macroautophagy appears to constitute an important mech-
anism of atrial cardiomyocyte remodeling in atrial ﬁbrillation
(AF).
• Endoplasmic reticulum stress is the upstream pathway
inducing autophagy in AF.
• Oral treatment with the chemical chaperone 4-phenyl
butyrate inhibited endoplasmic reticulum stress and coun-
teracted disease progression in a dog model of AF.
What Are the Clinical Implications?
• Pharmacological inhibition of endoplasmic reticulum stress
and downstream autophagy may offer novel therapeutic
strategies to limit disease progression in clinical AF.
• The endoplasmic reticulum stress inhibitor 4-phenyl buty-
rate, which is already approved for clinical use in urea cycle
disorders, offers an immediate candidate to test the
concept in clinical AF.
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performed at 1-Hz stimulation at 37°C. Live recordings were
further processed by use of the software ImageJ. The relative
value of ﬂuorescence signals between experiments was
determined using the following calibration: Fcal=F1/F0,
where F1 is the ﬂuorescent dye signal at any given time
and F0 is the ﬂuorescent signal at rest. Mean values and
SEMs from each experimental condition were based on 7
consecutive CaTs in at least 50 cardiomyocytes.
Drug Treatment
Pepstatin A, baﬁlomycin A1 (BAF), tunicamycin, rapamycin,
and 4PBA were dissolved, according to manufacturer’s
instructions. HL-1 cardiomyocytes were treated with 4PBA
(10 mmol/L), tunicamycin (5 lg/mL), and rapamycin
(50 nmol/L) 8 hours before pacing. Pepstatin A (10 lmol/
L) and BAF (10 nmol/L) were added 30 minutes before
normal or tachypacing.
Drosophila Stocks, Tachypacing, and Heart Wall
Contraction Assays
For all experiments, w1118 strains were used. All ﬂies were
maintained at 25°C on standard medium. After fertilization,
adult ﬂies were removed and drugs were added to the medium
containing ﬂy embryos. Drosophila embryos and larvae were
treatedwith 4PBA (100 mmol/L), pepstatin A (100 lmol/L), or
BAF (100 nmol/L) during development. Controls were treated
with the vehicle, 2% dimethyl sulfoxide. After 2 days, prepupae
were selected for tachypacing, as previously described.22
Groups of at least 5 prepupae were subjected to tachypacing
(5 Hz for 20 minutes, 20-V and 5-millisecond pulses; Table 1)
with a C-Pace EP Culture Stimulator. Before and after tachy-
pacing, videos of spontaneous heart wall contractions in whole
prepupae were recorded for 30 seconds. Heart wall contrac-
tions were analyzed with IonOptix software.
Western Blot Analysis
Western blot analysis was performed, as previously described.3
Brieﬂy, equal amounts of total protein in SDS-PAGE sample
buffer were separated on SDS-PAGE 4% to 20% Precise Tris-
HEPES gels. After transfer to nitrocellulose membranes,
membranes were incubated with primary antibodies, followed
by incubation with horseradish peroxidase–conjugated anti-
mouse or anti-rabbit secondary antibodies. Signals were
detected by the Western Lightning Ultra method and quantiﬁed
by densitometry via the software Gene Gnome, Gene tools. The
following antibodies were purchased: rabbit anti–phosphory-
lated protein kinase B (Akt; Ser473), rabbit anti-Akt, rabbit anti-
LC3B, rabbit anti-SQSTM1/p62, rabbit anti–phosphorylated
eIF2a (Ser51), rabbit anti–phosphorylated S6 ribosomal protein
(Ser235/236), mouse anti-S6 ribosomal protein, rabbit anti–
phosphorylated mTOR (Ser2448/2481), rabbit anti-mTOR,
mouse anti-eIF2a, mouse anti-HSPA5, mouse anti–b-actin,
and mouse anti-GAPDH; rabbit anti–b-myosin heavy chain 7
(MHC) was a kind gift of Professor J. Van der Velden.
Quantitative Real-Time Polymerase Chain
Reaction
Total RNA was isolated from HL-1 cardiomyocytes using the
nucleospin RNA isolation kit. First-strand cDNA was gener-
ated by M-MLV reverse transcriptase and random primers.
Relative changes in transcription level were determined using
the CFX384 Real-Time System C1000 Thermocycler in
combination with SYBR green ROX-mix. Calculations were
performed using the comparative threshold cycle method,
according to User Bulletin 2. Fold inductions were adjusted
for GAPDH levels.
Primer pairs used included the following: ATF4, GTCCGTTA-
CAGCAACACTGC (forward) and CCACCATGGCGTATTAGAGG
(reverse); ATF6, AAGAGAAGCCTGTCACTG (forward) and
GGCTGGTAGTGTCTGAAT (reverse); CHOP, GACCAGGTTCTGC
TTTCAGG (forward) and CAGCGACAGAGCCAGAATAA (re-
verse); HSPA5, ATCTTTGGTTGCTTGTCGCT (forward) and
ATGAAGGAGACTGCTGAGGC (reverse); autophagy gene 12,
CTCCACAGCCCATTTCTTTG (forward) and AACTCCCGGAGAC
ACCAAG (reverse); and GAPDH, CATCAAGAAGGTGGTGAAGC
(forward) and ACCACCCTGTTGCTGTAG (reverse). Polymerase
chain reaction efﬁciencies for all primer pairs were between
90% and 110%.
Immunoﬂuorescent Staining and Confocal
Analysis
HL-1 cardiomyocytes were untransfected or transiently
transfected with green ﬂuorescent protein–LC3B for 48 hours
and paced at 1 Hz (normal pacing) or 6 Hz (tachypacing). This
was followed by ﬁxation with 4% formaldehyde for 15 minutes
at room temperature and washing 3 times with PBS; then,
they were permeabilized and blocked with 0.3% Triton X-100
and 5% fetal bovine serum in PBS (1 hour at room
Table 1. Comparison of the Different Models Used
Model NP Group, Hz (bpm) TP Group, Hz (bpm)
HL-1 1 (60) 6 (360)
Drosophila 1.5 (90) 5 (300)
Dog 1.3 (80) 10 (600)*
Bpm indicates beats per minute; NP, normal-paced; and TP, tachypaced.
*Please note that 600 bpm atrial tachypacing in the dog induces atrial ﬁbrillation (AF),
with atrial-tissue responses at 6 to 8 Hz. This model is intentionally used to produce
sustained AF, thereby mimicking the clinical situation.
DOI: 10.1161/JAHA.117.006458 Journal of the American Heart Association 3























temperature). Endogenous LC3B was visualized by the anti-
LC3B antibody and a secondary Alexa-488–labeled anti-rabbit
antibody; endogenous MHC was visualized by the anti-MHC
(kind gift of Professor J. Van der Velden) and a secondary
ﬂuorescein isothiocyanate–labeled anti-rabbit antibody.
Endogenous LC3B, green ﬂuorescent protein–LC3B puncta,
indicative of autophagosomes, and MHC were visualized by
confocal microscopy and captured at 9125 magniﬁcation.
The number of puncta was counted manually from at least 2
independent experiments using ImagePro. Mean values and
SEMs from each experimental condition were based on at
least 20 cardiomyocytes in case of transfection and at least
50 in case of drug treatment.
In Vivo Dog Model for AF
Adult mongrel dogs were divided into 3 groups: nonpaced, atrial
tachypaced (ATP; Table 1) to maintain AF, or ATP with sodium
salt of PBA (Na-PBA) treatment (300 mg/kg per day, orally). All
dogs underwent the same surgical procedure, AF induction
measurements, and cardiomyocyte contractility and electro-
physiological measurements. The dogs were anesthetized with
acepromazine (0.07 mg/kg IM), ketamine (5.3 mg/kg IV),
diazepam (0.25 mg/kg IV), and isoﬂurane (1.5%); then, they
were intubated and ventilated. One bipolar pacing lead was ﬁxed
into the right atrial (RA) appendage via the left jugular vein under
ﬂuoroscopic guidance. The tipwas connected to a programmable
pacemaker. Results in 7 ATP dogs with Na-PBA were compared
with 7 tachypaced dogs without treatment and 7 nonpaced
control dogs. Na-PBA was given orally (300 mg/kg per day),
starting 3 days before and continuing throughout ATP. For the
ATP and ATP with Na-PBA groups, the pacemakers were turned
on 24 hours after surgery to stimulate the RA at 600 beats per
minute for 7 successive days. The ECG was checked daily to
ensure AF during pacing. At the end of the study, all dogs were
anesthetized with morphine (2 mg/kg SC) and a-chloralose
(120 mg/kg IV bolus, followed by 29.25 mg/kg per hour IV
infusion); then, they were intubated and ventilated. Body
temperature was maintained at 37°C. After midline sternotomy,
the pericardium was opened and 2 bipolar electrodes were ﬁxed
to the RA appendage (1 for pacing and 1 for signal recording). For
AF induction, the RA was paced at 50 Hz for 10 seconds. A total
of 5 to 10 AF episodes were recorded to calculate the mean AF
duration in each dog. An AF episode >10 minutes was consid-
ered sustained, and the electrophysiological study was termi-
nated. Cardioversion was avoided to prevent tissue damage,
which precludes further cellular and molecular studies.
Atrial Cardiomyocyte Isolation
After electrophysiological study, the heart was excised and
immersed in oxygen-saturated Tyrode solution (in mmol/L):
NaCl 136, KCl 5.4, MgCl2 1, CaCl2 2, NaH2PO4 0.33, HEPES 5,
and dextrose 10 (pH 7.35), by NaOH. The left atrium (LA) was
isolated from the heart with an intact blood supply. The left
circumﬂex coronary artery was cannulated and perfused with
Ca2+ (1.8 mmol/L), followed by Ca2+-free Tyrode solution
perfusion for 10 minutes. All leaking branches were ligated.
The tissue was then perfused with Ca2+-free Tyrode solution
containing 150 U/mL collagenase and 0.1% BSA for 60 min-
utes. Digested LA tissue was harvested and carefully stirred.
Isolated cells were centrifuged (500 rpm, 3 minutes) to
separate cardiomyocytes from ﬁbroblasts. Cardiomyocytes
were stored in Tyrode solution containing 200 lmol/L Ca2+
for Ca2+-imaging studies.
Cardiomyocyte Ca2+ Imaging and Cellular
Contractility Assessment
Isolated cardiomyocytes were stimulated at 1 Hz, and all
measurements were performed at 352°C. Cell-Ca2+ record-
ing was obtained, as previously described, with the use of
Indo-1 AM.3,23 Cells were exposed to UV light (wavelength,
340 nm), and the exposure was controlled with an electronic
shutter to minimize photographic bleaching. Emitted light was
reﬂected into a spectral separator, passed through parallel
ﬁlters at 400 and 500 nm (10 nm), detected by matched
photomultiplier tubes, and electronically ﬁltered at 60 Hz.
Background ﬂuorescence was removed by adjusting the 400-
and 500-nm channels to 0 over an empty ﬁeld of view near
the cell. Fluorescence signal ratios (R) were recorded and
converted to [Ca2+]i following the equation developed by
Grynkiewicz et al24: [Ca2+]i=Kdb [(RRmin)/(RmaxR)], where
b is the ratio of the 500-nm signals at low and saturating
[Ca2+]i. Intracellular Kd for Indo-1 was 844 nm. Cell and
sarcomere contractility was detected by automatic edge
detection, and 5 successive beats were averaged for each
measurement.
Cell Electrophysiological Recordings
Borosilicate glass electrodes ﬁlled with pipette solution were
connected to a patch-clamp ampliﬁer. Electrodes had tip
resistances of 2 to 4 MΩ. For perforated-patch recording,
nystatin-free intracellular solution was placed in the tip of the
pipette by capillary action (30 seconds); then, pipettes were
back-ﬁlled with nystatin-containing (600 lg/mL) pipette
solution. Data were sampled at 5 kHz and ﬁltered at 1 kHz.
Whole cell currents are expressed as densities (pA/pF).
Junction potentials between bath and pipette solutions
averaged 10.5 mV and were corrected for APs only. Tyrode
solution contained the following (in mmol/L): NaCl 136, CaCl2
1.8, KCl 5.4, MgCl2 1, NaH2PO4 0.33, dextrose 10, and HEPES
5, titrated to pH 7.3 with NaOH. The pipette solution for AP
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recording contained the following (mmol/L): GTP 0.1, potas-
sium-aspartate 110, KCl 20, MgCl2 1, MgATP 5, HEPES 10,
sodium-phosphocreatine 5, and EGTA 0.005 (pH 7.4, KOH).
The extracellular solution for Ca2+-current measurement
contained the following: tetraethylammonium chloride 136,
CsCl 5.4, MgCl2 1, CaCl2 2, NaH2PO4 0.33, dextrose 10, and
HEPES 5 (pH 7.4, CsOH). Niﬂumic acid (50 lmol/L) was
added to inhibit Ca2+-dependent Cl current, and 4-aminopyr-
idine (2 mmol/L) was added to suppress Ito. The pipette
solution for Ca2+-current recording contained the following (in
mmol/L): CsCl 120, tetraethylammonium chloride 20, MgCl2
1, EGTA 10, MgATP 5, HEPES 10, and Li-GTP 0.1 (pH 7.4,
CsOH).
Patient Material
Before surgery, 1 investigator assessed patient characteris-
tics (Table 2), as described before.7 All patients were
euthyroid and had normal left ventricular function. RA and
LA appendages were obtained from all patients. After
excision, the atrial appendages were immediately snap frozen
in liquid nitrogen and stored at 85°C. The study conforms to
the principles of the Declaration of Helsinki. The institutional
review board approved the study, and patients gave written
informed consent. Because of the low tissue yield per patient,
not all experiments could be performed with each tissue
sample. Therefore, at least 5 samples per group were used for
experiments.
Statistical Analysis
Results are expressed as meanSEM of at least 3 indepen-
dent experiments. Statistical analysis was performed using a
Student t test for single comparison between 2 groups. For
analysis involving >2 groups, statistical comparison was
performed using a 1-way ANOVA. When showing signiﬁcance,
individual group differences were assessed using a Bonfer-
roni-corrected t test. Correlations were estimated using
Pearson correlation and tested to be signiﬁcantly nonzero
using Pearson correlation tests. All P values were 2 sided.
P≤0.05 was considered statistically signiﬁcant. SPSS version
20 was used for all statistical evaluations.
Results
Tachypacing of Cardiomyocytes Induces
Autophagy
To explore whether tachypacing induces autophagy, the
autophagy markers p62 and LC3B were tested. P62 is
sequestrated to autophagosomes during autophagy and
degraded on fusion with the lysosome; reduced levels of
p62 are an indication of autophagic activation.25–27 LC3B-II
is a protein produced from LC3B-I on activation of autophagy
and is also incorporated into autophagosomes; LC3B-II levels
correlate with the induction of autophagy.25–27 Tachypacing
of HL-1 atrial cardiomyocytes, in which 8-hour tachypacing
produces changes resembling those reported in persistent
AF (PeAF) in humans,3,28 activates autophagy, as demon-
strated by a time-dependent decrease in the expression of
p62 and increase in LC3B-II levels (Figure 1A through 1C).
No such changes were noted in cardiomyocytes paced at
1 Hz (ie, their average intrinsic ﬁring frequency; Figure S1).
For the sake of clarity, results for normal-paced cardiomy-
ocyte data shown in the ﬁgures without other speciﬁcation
were obtained after 8 hours of pacing. Furthermore, HL-1
atrial cardiomyocytes show normal morphological character-
istics and are viable during normal pacing and tachypacing,
as assessed by bright-ﬁeld microscopy (Figure S2). Tachy-
pacing also induces a clear redistribution of LC3B into
discrete perinuclear puncta in both untransfected cardiomy-
ocytes and LC3B–green ﬂuorescent protein transfected
cardiomyocytes (Figure 1D through 1F, Figure S3), support-
ing autophagosome formation.29 Next, we determined the
autophagic ﬂux, to discriminate between the induction of
autophagy and decreased degradation of autophagosomes,
by blocking autophagosome-lysosome fusion with (Figure 1G
and 1H).27,30 BAF pretreatment further increases LC3B-II
levels of tachypaced cardiomyocytes, but did not affect
normal-paced cardiomyocytes (Figure 1G and 1H, Figures S4
and S5). This ﬁnding, together with reduced p62 levels,
Table 2. Demographic and Clinical Characteristics of






RAA 17 (100) 25 (89)
LAA 14 (82) 27 (96)
Age, meanSEM, y 585 613
Duration of AF, median (range),
mo
 8 (0.1–56)
Underlying heart disease/surgical procedure
Lone AF/maze 0 (0) 7 (25)*
CAD/MVI 17 (100) 21 (75)*
Medication
Digoxin 1 (6) 13 (46)†
Calcium antagonists 9 (53) 10 (36)
Blockers 17 (100) 9 (32)‡
Values are represented as number (percentage) of patients unless otherwise indicated.
AF indicates atrial ﬁbrillation; CAD, coronary artery disease; LAA, left atrial appendage;
maze, atrial arrhythmia surgery; MVI, mitral valve insufﬁciency; PeAF, persistent AF; RAA,
right atrial appendage; and SR, sinus rhythm.
*P≤0.05, †P≤0.01, ‡P≤0.001 vs SR.
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Figure 1. Tachypacing (TP) induces autophagosome formation and
enhanced activation of autophagy. A, Representative Western blot of TP-
induced autophagy markers p62 (molecular weight [MW], 62), LC3B-I and
LC3B-II (MWs, 14 and 16, respectively), and loading control GAPDH (MW, 37).
HL-1 cardiomyocytes were normal paced (NP) or TP for the duration indicated.
B, Quantiﬁed data showing a signiﬁcant reduction in p62 levels after 6 or
more hours of TP (N=4). C, Quantiﬁed data showing a signiﬁcant increase in
LC3B-II levels, beginning after 2 hours of TP (N=5). D, Confocal images of TP
HL-1 cardiomyocytes, for the period as indicated, transfected with LC3B–
green ﬂuorescent protein (GFP) plasmid. E, Confocal images of TP HL-1
cardiomyocytes for the period as indicated. Endogenous LC3B was visualized
by immunostaining. Green puncta indicate autophagosomes. F, Quantiﬁed
data showing accumulation of LC3B-GFP punctae/cardiomyocytes during TP
(n/N=35/3). G, Representative Western blot of HL-1 cardiomyocytes NP vs TP
for the duration, as indicated, in the presence or absence of baﬁlomycin A1
(BAF). H, Quantiﬁcation of the autophagic ﬂux by determining the difference in
LC3B-II levels in the presence vs absence of BAF (N=4). Note that all NP data
are shown after 8 hours of observation. *P≤0.05, **P≤0.01, ***P≤0.001 vs
NP.
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indicates that tachypacing increases functional autophagic
activity in HL-1 atrial cardiomyocytes.
ER Stress Is Associated With Autophagy in a
Tachypaced Cardiomyocyte Model
To investigate which upstream pathway activates autophagy,
we ﬁrst examined the mTOR. mTOR assembles into 2
complexes, mTOR complex (mTORC) 1 and mTORC2; both
complexes become activated by mTOR phosphorylation,
although at different sites, after which they attenuate
autophagy.12,31 To test whether tachypacing-induced autop-
hagy results from the inhibition of mTOR signaling, we
determined total mTOR, phosphorylation of mTOR at S2448
for mTORC1 and S2481 for mTORC2, and their respective
downstream targets, ribosomal protein S6 and Akt (Figure 2A
through 2D). Tachypacing does not affect phosphorylation of
mTOR at S2448 or S2481; it also does not affect phospho-
rylation of the mTORC1 downstream effector ribosomal
protein S6 at S235/S236. However, tachypacing signiﬁcantly
increases phosphorylation of Akt at S473 (Figure 2D). Given
the increased Akt phosphorylation, which is independent of
mTORC2, we next examined involvement of ER stress
signaling in tachypacing-induced autophagic ﬂux; Akt S473
phosphorylation is observed during ER stress,32 and ER stress
is an important regulator of autophagy.14 A role of ER stress
was suggested by the ﬁnding that tachypacing strongly
increases phosphorylation of its downstream effector eIF2a
(Figure 3A and 3B, Figure S6), which, on phosphorylation,
induces transcription of ER stress and autophagy genes (ie,
ATF4, ATF6, CHOP, HSPA5, and ATG12; Figure 3C). In
addition, tachypacing gradually induced protein levels of
HSPA5 (Figure S7), an endogenous ER chaperone-protein
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Figure 2. Tachypacing (TP)–induced autophagy does not involve mammalian target of rapamycin
complex (mTORC) signaling. Top panels: Western blots of proteins within mTORC signaling. Bottom
panels: Quantiﬁed data of the ratio of phosphorylated proteins normalized for basal protein levels.
Phosphorylated mTOR S2448 (mTORC1; molecular weight [MW], 289; N=3; A), phosphorylated
mTOR S2481 (mTORC2; MW, 289; N=3; B), phosphorylated ribosomal protein S6 (S6RP) S235/236
(downstream of mTORC1; MW, 32; N=3; C), and phosphorylated protein kinase B (Akt) S473
(downstream of mTORC2 and endoplasmic reticulum stress; MW, 60; N=3; D) in response to TP for
the duration, as indicated, compared with normal pacing (NP). Note that all NP data shown are after
8 hours of observation. **P≤0.01, ***P≤0.001 vs NP.
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is the upstream activator of autophagy in the tachypaced
cardiomyocyte model.
To extend the ﬁndings to human AF, we examined
autophagy, ER stress, and markers of cardiac remodeling in
atrial appendages of patients with PeAF along with control
patients in SR. Patients with PeAF showed an accumulation of
autophagosomes and autolysosomes and the presence of
myolysis (degradation of sarcomeres) on electron microscopic
examination, which is absent in patients in SR (Figure 4A
through 4D).34 Autophagy is further evidenced in patients with
AF by enhanced LC3B-II induction and decreased levels of p62
compared with patients in SR (Figure 4E). The ER stress
chaperone-protein HSPA5 showed a trend towards increased
expression in patients with PeAF compared with patients in
SR. Previously, we reported on structural remodeling involving
degradation of contractile proteins in these patients.4,7
Involvement of autophagy in structural remodeling and AF
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Figure 3. Tachypacing (TP) augments levels of endoplasmic reticulum (ER) stress markers and
the autophagy gene ATG12. A, Representative Western blot of phosphorylated eIF2a S51
(molecular weight [MW], 38), an ER stress marker, basal eIF2a (MW, 36), and GAPDH levels during
normal pacing (NP) or in response to TP for the indicated duration. B, Quantiﬁed data of the ratio of
phosphorylated eIF2a S51 normalized for basal eIF2a protein levels (N=3). C, Quantitative real-time
polymerase chain reaction of ER stress markers ATF4, ATF6, CHOP, and heat shock protein (HSP)
A5 and the autophagy-related gene ATG12 in response to TP for the indicated duration relative to
NP (N=3). Note that all NP data shown are after 8 hours of observation. **P≤0.01, ***P≤0.001 vs
NP.
DOI: 10.1161/JAHA.117.006458 Journal of the American Heart Association 8























expression with cardiac troponins (I and T) and a-tubulin
expression in patients with PeAF and those in SR (Figure 4F
through 4H); there was an inverse correlation with the amount
of myolysis (Figure 4I). Levels of p62 also correlated with
HSPA5 levels (Figure 4J), suggesting that an ER stress
response is associated with autophagy and AF progression.
Although 1 data point seems to be an outlier, statistical
analysis showed it did not qualify as such. Nevertheless, to
exclude undue inﬂuence of this data point on correlations, we
have repeated the analyses, omitting this data point. For most
analyses, correlation remained statistically signiﬁcant, with
the exception of cardiac troponin T and myolysis (Figure 4F:
R=0.43, P=0.075; Figure 4G: R=0.74, P<0.001; Fig-
ure 4H: R=0.49, P<0.05; Figure 4I: R=0.46, P=0.056;
Figure 4J: R=0.62, P<0.05).
The correlation of autophagy markers with degradation of
contractile proteins and the amount of structural remodeling
suggest a biologically relevant contribution of this pathway to
AF-induced derailment of cardiomyocyte proteostasis and
disease progression.
Inhibition of ER Stress Attenuates Autophagy and
Protects From Cardiac Remodeling
The contribution of AF-induced ER stress and the subsequent
enhanced autophagic ﬂux to derailment of cardiomyocyte
proteostasis and disease progression was tested by pharma-
cological and genetic manipulations in experimental model
systems for AF. The orphan drug, 4PBA, in clinical use to treat
urea cycle disorders,35–37 has recently been recognized as an
R=0.53, P<0.05



















































































































































Figure 4. Patients with persistent atrial ﬁbrillation (PeAF) show markers of endoplasmic reticulum (ER) stress and autophagy. A, Electron
microscopic image of left atrial appendage (LAA) of a patient in sinus rhythm (SR), showing normal sarcomere structures and absence of
autophagosomes and autolysosomes. B, Image of LAA of a patient in SR, showing normal sarcomere structures and absence of perinuclear
autophagosomes and autolysosomes at higher magniﬁcation. C, Electron microscopic image of LAA of a patient with PeAF, which shows
the presence of autophagosomes and autolysosomes with an electron-dense core with a perinuclear (N) localization. D, Image of LAA of a
patient with PeAF at a higher magniﬁcation, showing the presence of autophagosomes and autolysosomes. E, Top panel: Representative
Western blot of the autophagy markers LC3B-II and p62 and the ER stress chaperone-protein heat shock protein (HSP) A5 in atrial
appendages of patients with PeAF vs those in SR. Bottom panel: Quantiﬁed data of the autophagy markers LC3B-II and p62 and the ER
stress chaperone-protein HSPA5 in atrial appendages of patients with PeAF vs those in SR. F through J, Signiﬁcant correlations between
levels of the autophagy marker p62 and markers of cardiomyocyte structural remodeling in patients with PeAF and patients in SR. F,
Cardiac troponin T (cTnT). G, Cardiac troponin I (cTnI). H, a-Tubulin (Tub). I Myolysis. J, HSPA5. RAA indicates right atrial appendage.
**P≤0.01, ***P≤0.001 vs SR.
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inhibitor of ER stress by virtue of its chemical chaperone
properties.38,39 To explore its potential as a therapeutic agent
in AF, we examined its properties in tachypaced cardiomy-
ocytes, Drosophila, and a dog model of AF.
In tachypaced HL-1 cardiomyocytes, 4PBA limits ER stress
and prevents activation of autophagy, as demonstrated by
normalization of phosphorylated eIF2a expression and LC3B-II
and attenuation of p62 breakdown (Figure 5A and 5B). In
addition, 4PBA treatment prevents tachypacing-induced accu-
mulation of the contractile protein MHC in perinuclear puncta
in HL-1 cardiomyocytes (Figure 5C and 5D). The protective
4PBA effects are mediated via upstream ER stress inhibition,
because downstream inhibition of the autophagic process by
pepstatin A (a lysosomal cathepsin D/E inhibitor) or BAF
(a lysosomal fusion inhibitor) attenuated p62 degradation but
did not normalize the phosphorylation of eIF2a, LC3B-II
expression, and the formation of perinuclear MHC puncta on
tachypacing (Figure 5A through 5D).
Next, we determined whether ER stress results in tachy-
pacing-induced contractile dysfunction. HL-1 cardiomyocytes
were pretreated with 4PBA, which caused protection against
loss of CaTs in 8-hour tachypaced cardiomyocytes (Figure 5E
and 5F, Figure S8A and S8B, Videos S1 through S4). Similar
protective effects against CaT loss were observed in tachy-
paced HL-1 cardiomyocytes overexpressing the endogenous
ER chaperone-protein HSPA5, indicating that ER stress is
involved in contractile dysfunction (Figure 5G and 5H, Videos
S5 through S8). To directly assess whether ER stress is
associated with autophagy and contractile dysfunction, HL-1
cardiomyocytes were transfected with eIF2a mutants (wild
type, constitutively phosphorylated [S51D], or constitutively
nonphosphorylated [S51A]), followed by tachypacing. Tachy-
paced HL-1 cardiomyocytes overexpressing the nonphospho-
rylated eIF2amutant were protected from CaT loss, in contrast
to cardiomyocytes overexpressing the wild-type or constitu-
tively phosphorylated eIF2a mutants (Figure 5I and 5J).
Normal-paced HL-1 cardiomyocytes, transfected with the
eIF2a mutants, showed no differences in CaT amplitude
compared with nontransfected cardiomyocytes (Figure S8C
and S8D). The ﬁndings indicate that activation of the ER stress
pathway is an important modulator of contractile dysfunction.
In addition, inhibition of autophagic ﬂux by preincubating HL-1
cardiomyocytes with the autophagy inhibitors pepstatin A and
BAF was also protective against tachypacing-induced CaT loss.
This again emphasized the role of ER stress–associated
autophagy in contractile function (Figure 5E and 5F, Figure S8A
and S8B, Videos S9 through S12). Pepstatin A and BAF effects
are not conveyed via indirect modulation of ER stress, because
neither of the drugs inﬂuenced HSPA5 expression levels, as
suggested before (Figure S9).40
To extend these ﬁndings to a multicellular experimental
animal model for tachypacing-induced contractile dysfunction,
similar experiments were conducted in Drosophila.3,22 Com-
parable to ﬁndings in tachypaced HL-1 cardiomyocytes,
inhibition of ER stress (4PBA) and autophagy (BAF) attenuates
tachypacing-induced dysfunction in heart wall contractions in
Drosophila (Figure 5K and 5L, Videos S13 through S18),
whereas pepstatin A is not protective and toxic at the
concentrations applied. Moreover, activators of ER stress
(tunicamycin) and autophagy (rapamycin) resulted in ER stress
and contractile dysfunction in tachypaced HL-1 cardiomy-
ocytes and Drosophila (Figure S10).
ER Stress Attenuation Relieves Autophagy and
Protects From Cardiac Remodeling in an in Vivo
Animal Model
To obtain proof of concept that ER stress is involved in AF
promotion in a large animal model for AF, dogs were subjected
to 7 days of ATP(equal to persistent human AF41), to induce AF-
associated atrial remodeling, and were treated with the orally
administered Na-PBA (300 mg/kg per day). In isolated atrial
cardiomyocytes, Na-PBA treatment protects from tachypacing-
induced electrical changes, including shortening of action
potential duration and reductions in L-type Ca2+ channel
current (Figure 6A and 6B). In addition, Na-PBA treatment
prevents tachypacing-induced abnormalities in Ca2+ handling
and associated hypocontractility of isolated atrial cardiomy-
ocytes (Figure 6C through 6F). Finally, Na-PBA conserved the
effective refractory period at various sites at both RA and LA and
signiﬁcantly attenuated the vulnerability to AF induction
(Figure 6G and 6H). In addition, the protective effect of Na-
PBA was not via modulation of HDAC activity, because HDAC
levels were not altered by Na-PBA treatment, as has been
suggested before (Figure S11).42 Furthermore, Na-PBA reduces
markers of ER stress and autophagy in LA tissue of tachypaced
dogs, as demonstrated by an increase in p62 level and
reductions in LC3B-II and HSPA5 levels compared with
nontreated tachypaced dogs (Figure 7A through 7C). More-
over, Na-PBA treatment protected against MHC reduction in
tachypaced dogs (Figure 7D), suggesting that attenuation of ER
stress results in conservation of contractile protein expression.
Thus, tachypacing induces ER stress–triggered autophagic
ﬂux, which plays a prominent role in cardiomyocyte remod-
eling and AF progression (Figure 8).43 Findings from a
clinically relevant dog model for AF indicate that the chemical
chaperone 4PBA protects the heart against AF, making 4PBA
a potentially interesting drug candidate for treating clinical AF.
Discussion
In the current study, we report that ER stress–associated
enhanced autophagic ﬂux appears to constitute an important
DOI: 10.1161/JAHA.117.006458 Journal of the American Heart Association 10























mechanism of cardiac remodeling in tachypaced cardiomy-
ocytes, Drosophila, dogs, and atrial biopsy specimens from
patients with AF. We provide data to show that blocking ER
stress, by the chemical chaperone 4PBA, or overexpressing a
phosphorylation-blocked mutant of eIF2a inhibits activation of
autophagy and, thereby, suppresses cardiomyocyte remodel-
ing in both in vitro and in vivo AF models. Thus, our study
points to ER stress as a potential novel druggable target for
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Figure 5. Inhibition of endoplasmic reticulum (ER) stress and autophagy protects against
tachypacing (TP)–induced contractile dysfunction in HL-1 cardiomyocytes and Drosophila
melanogaster. A, Representative Western blot of ER stress marker (eIF2a-PS51) and autophagy
markers (LC3B-II and p62) in HL-1 cardiomyocytes pretreated with dimethyl sulfoxide (DMSO;
control [C]), the autophagy modulator pepstatin A (PepA) or baﬁlomycin A1 (BAF), or the
molecular chaperone 4-phenyl butyrate (4PBA). B, Quantiﬁed data showing that HL-1
cardiomyocytes treated with 4PBA reveal attenuation of TP-induced increase in eIF2a-PS51,
LC3B-II induction, and reduction in p62. PepA and BAF inhibit lysosomal cathepsin D/E and
lysosomal fusion, respectively, and therefore result in an induction of LC3B-II levels and
attenuation of p62 reduction without affecting upstream eIF2a-PS51 levels. Open bars represent
normal-paced (NP) cardiomyocytes, whereas closed bars represent TP cardiomyocytes after
8 hours of observation. N=3. C, Confocal images of NP and TP HL-1 cardiomyocytes after
8 hours of observation, stained for myosin heavy chain with DMSO (C), 4PBA, BAF, or PepA
pretreatment. D, Quantiﬁed data showing the number of puncta for the conditions as indicated,
all obtained after 8 hours of observation. 4PBA pretreatment protects against the formation of
perinuclear puncta (n/N=60/3). E, Representative Ca2+ transients (CaT; 5 seconds) of HL-1
cardiomyocytes after NP or TP. HL-1 cardiomyocytes were pretreated with the autophagy
modulators PepA or BAF, or the chemical chaperone 4PBA, followed by NP or TP and
measurement of CaT. F, Quantiﬁed CaT amplitude of HL-1 cardiomyocytes after NP or TP (n/
N=60/4). HL-1 cardiomyocytes were pretreated with the autophagy modulators PepA or BAF or
the ER chaperone 4PBA. G, Representative CaT (5 seconds) of HL-1 cardiomyocytes transfected
with empty plasmid (C) or ER chaperone heat shock protein (HSP) A5, followed by NP or TP. H,
Quantiﬁed CaT amplitude of NP and TP HL-1 cardiomyocytes transiently transfected with empty
plasmid or HSPA5 (n/N=30/3). I, Representative CaT (5 seconds) of HL-1 cardiomyocytes
transfected with empty plasmid (C), eIF2a wild-type, nonphosphorylated (S52A), or phosphory-
lated mimetic (S52D) mutant and followed by NP or TP. J, Quantiﬁed CaT amplitude of NP and TP
cardiomyocytes transiently transfected with empty plasmid (C), eIF2a wild-type, constitutively
nonphosphorylated (S52A), or constitutively phosphorylated (S52D) mutant (n/N=30/3). K,
Representative heart wall contractions of Drosophila monitored before TP (sinus rhythm [SR]) and
after TP with DMSO (C) or PepA, BAF, or 4PBA pretreatment. L, Quantiﬁed data showing heart
wall contraction rates of Drosophila before and after TP with DMSO (C) or PepA, BAF, or 4PBA
treatment. Open bars represent NP (in HL-1 cardiomyocytes) or spontaneous heart rate (SR; in
Drosophila), and closed bars represent TP HL-1 cardiomyocytes or Drosophila. N=9 to 15
prepupae for each group. Note that all NP data shown are after 8 hours of observation. *P≤0.05,
**P≤0.01, ***P≤0.001 vs control NP or before TP; #P≤0.05, ##P≤0.01, ###P≤0.001 vs control
(after) TP.
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cardiac remodeling in AF and proposes that 4PBA may
emerge as a novel lead compound for the development of
agents to attenuate AF progression.
Prominent Role of ER Stress–Associated
Autophagy in Cardiomyocyte Remodeling
Although it is recognized that the increased atrial activation
rate constitutes a major driving force for cardiac remodeling
in AF,1 molecular events leading to remodeling have been
poorly identiﬁed. We examined both experimental and clinical
AF models that equal persistent human AF, which show
reversible electrical and irreversible structural remodel-
ing.3,8,28,44,45 We were able to reveal a prominent role for
ER stress–associated enhanced autophagic ﬂux in cardiomy-
ocyte remodeling and AF progression using various pharma-
cological and genetic manipulations of the ER stress pathway
(Figure 8). First, tachypacing-induced contractile dysfunction
of HL-1 cardiomyocytes coincided with activation of known
key players of this pathway. These include both phosphory-
lation of the ER stress regulator eIF2a at S51 and down-
stream expression of the stress-responsive transcripts ATF4
and ATF6. In turn, ATF4 and ATF6 activate autophagy,10 via
enhanced expression of CHOP and the autophagy genes
ATG12 and LC3B, resulting in the elongation of autophago-
somes and a sustained and excessive autophagic ﬂux, as
observed in tachypaced HL-1 cardiomyocytes.12,46–48 Second,
our data demonstrate that induction of ER stress represents
the upstream event in tachypacing-elicited contractile-protein
accumulation and contractile dysfunction. Genetic overex-
pression of a phosphorylation-blocked eIF2a protein or the ER
chaperone HSPA5 abrogated both autophagy and contractile
dysfunction. Knockdown of autophagy genes, such as ATG5 or
ATG7, was avoided because of the detrimental effects in
healthy cardiomyocytes.15,49–51 A prominent role for ER
stress–induced autophagy in AF promotion is supported by
pharmacological interventions. We observed that inhibition of
the autophagic process by pepstatin A (a lysosomal cathepsin
D/E inhibitor) or BAF (a lysosomal fusion inhibitor) protected
against contractile dysfunction, but did not prevent the ER
stress response and accumulation of contractile proteins
within the HL-1 cardiomyocytes. Pharmacological prevention
of ER stress by the chemical chaperone 4PBA precluded ER
stress–related autophagy and cardiac remodeling in tachy-
paced HL-1 cardiomyocytes and Drosophila, as well as in the
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Figure 5. Continued.
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ER stress and autophagy are also activated in clinical AF, as
evidenced by the presence of autophagosomes and autolyso-
somes in atrial heart tissue, enhanced LC3B-II expression, and
reduction in p62 levels in patients with PeAF. Although altered
proteasome function can inﬂuence p62 expression,52
proteasome function is not altered in AF,7 suggesting that
the reduction in p62 levels is a consequence of autophagic
ﬂux activation. Although there is only a trend towards an
increase in HSPA5 expression in patients with AF, diminished
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Figure 6. Sodium salt of phenyl butyrate (Na-PBA) protects against atrial remodeling in a dog
model for atrial ﬁbrillation (AF). Atrial tachypacing (ATP) induces atrial remodeling, measured as
shortening of action potential duration (ADP90; A), reduced L-type Ca2+ current (ICaL; B), and
increased diastolic calcium levels in cardiomyocytes (n=15–40 cardiomyocytes; C). D, Represen-
tative calcium transient (CaT) and cell shortening (CS) tracers for the conditions, as indicated.
Furthermore, ATP results in loss of CaT amplitude (E), loss of contractility (F), reduced adaptation of
the effective refractory period (ERP) at different basic cycle lengths (BCLs; G), and increased
duration of induced AF (H). All ATP-induced atrial remodeling end points were signiﬁcantly
attenuated by Na-PBA treatment. C indicates control. *P≤0.05, **P≤0.01, ***P≤0.001 vs C;
#P≤0.05, ##P≤0.01, ###P≤0.001 vs ATP.
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proteasome or autophagy, or exhaustion of the protein levels
may be the underlying cause.53 There is ongoing debate about
whether autophagy plays a beneﬁcial or detrimental role in
cardiac diseases.54,55 Excessive autophagy contributed to
age-related cardiac disease development, including heart
failure, hypertension-induced cardiac diseases, mitral regur-
gitation, and diabetic cardiomyopathy.16,19,56–58 Interestingly,
all these cardiac diseases are recognized to represent a
substrate for AF,59 suggesting a role for autophagic activation
in AF development. This is supported by the presence of
autophagosome accumulation in patients who developed
postoperative AF.60 On the other hand, in inherited
cardiomyopathies, autophagic activation was found to be
beneﬁcial.61–63 In inherited cardiomyopathies, proteotoxic
mutant proteins are likely cleared by autophagy. This
assumption is strengthened by a study showing that
autophagy could be induced as a cellular defense mechanism
against ER stress–mediated cell death by degrading protein
aggregates.14 Hence, it is clear that autophagic activation in
the diverse cardiac diseases is not uniform in its function, but
depends on the origin of cardiac disease; it can have either a
beneﬁcial (inherited cardiomyopathies) or detrimental (age-
related cardiac diseases) effect on the course and outcome of
the disease. Because protein aggregation has not been
observed in most age-related cardiac diseases, including AF,55
our ﬁndings suggest that the autophagic machinery becomes
overengaged with maladaptive consequences, possibly
because of divergent Ca2+ handling in the ER. The ER plays
a prominent role in proper cell function, because at least one









































































Figure 7. Sodium salt of phenyl butyrate (Na-PBA) protects against endoplasmic reticulum
stress and autophagy in a dog model for atrial ﬁbrillation. A, Top panel: Representative Western
blot. Bottom panel: Quantiﬁed data revealing a signiﬁcant reduction in p62 levels in atrial
tachypacing (ATP), which was not signiﬁcantly reduced by Na-PBA treatment compared with
control (C) dogs. B, Representative Western blot of LC3B-I/II and loading control b-actin
(molecular weight [MW], 43) in groups, as indicated. ATP causes signiﬁcant induction in LC3B-II
levels, which was signiﬁcantly reduced in case of Na-PBA treatment. C, Representative Western
blot of heat shock protein (HSP) A5, showing a trend (P=0.058) in induction of HSPA5, which
was not altered in Na-PBA–treated group. D, Representative Western blot of myosin heavy chain
(MHC; MW, 230) in groups, as indicated. ATP causes a signiﬁcant reduction in MHC, which was
not changed in case of Na-PBA treatment. N=7 dogs for each group. *P≤0.05 vs C, #P≤0.05 vs
ATP.
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chaperone proteins, especially HSPA5, assist in the correct
folding of the newly formed proteins.64 Reduced levels of
HSPA5, or calcium overload in the ER, cause proteins to
unfold and produce an ER stress response.65,66 Because
calcium overload plays a central role in experimental and
clinical AF progression6,67–69 and the ER is an important
organelle to buffer calcium, calcium overload is a plausible
trigger for ER stress, as observed in the current study. Further
experimental conﬁrmation of the role of ER calcium loading in
inducing the AF-related stress response is of interest.
Although our data demonstrate that (upstream) blockade of
ER stress, by 4PBA or a phosphorylation-blocked eIF2a
mutant, prevents progression of AF, (downstream) blockade
of autophagy elicited a similar effect, suggesting that
activation of autophagy mediates cardiomyocyte remodeling
in AF. In addition to clearance of damaged proteins, the
generation of adenosine triphosphate for the cardiomyocyte is
an important function of autophagy.70 It is known that AF
results in depletion of adenosine triphosphate levels. Car-
diomyocytes may compensate for energy loss by generating
adenosine triphosphate via autophagy at the expense of
degradation of sarcomeric proteins (myolysis), as observed in
experimental and clinical AF.4,7
Therapeutic Implications
From a translational perspective, the current results identify a
potential beneﬁt of pharmacological inhibition of ER stress as a
therapeutic strategy in clinical AF. Among the available
compounds, 4PBA seems promising, because this compound
is already approved for clinical use to treat urea cycle
disorders36,37,71 and is available under the trade names
Buphenyl (available in the United States since 1996) and
Ammonaps (available in Europe since 1999). 4PBA acts as a
chemical chaperone and alleviates ER stress by protecting from
aggregation of misfolded proteins. There are several ongoing
human trials with 4PBA, which target ER stress in various
clinical diseases featuring protein misfolding, including amy-
otrophic lateral sclerosis (NCT00107770), Huntington disease
(NCT00212316), spinal muscular atrophy (NCT00528268),
proteinuric nephropathies (NCT02343094), and cystic ﬁbrosis
(NCT00016744). Data from patients with urea cycle disorders
to date indicate that 4PBA is safe and displays minor adverse
effects,35 although conventional dosing is high (maximum,
20 g/d). In addition, our results indicate that cardiac remod-
eling in AF may also be modulated by inhibitors of
autophagy.47,72,73 However, treatment with autophagy
Figure 8. Proposed model for the role of autophagy and disease progression in atrial ﬁbrillation
(AF). AF triggers endoplasmic reticulum (ER) stress in cardiomyocytes, followed by the ER stress
response, which results in activation of ATF6 and upregulation of heat shock protein (HSP) A5
expression in an attempt to restore ER homeostasis. ER stress then activates downstream
phosphorylation of eIF2a.43 In turn, this results in the activation of the transcription factor ATF4,
which regulates the expression of autophagy genes and LC3B, causing activation of autophagy by
stimulating induction and elongation of autophagosomes. Initially, AF-induced activation of
autophagy may preserve cardiomyocyte proteostasis; however, excessive stress-induced autophagy
contributes to loss of contractile function and cardiac remodeling. ER stress–induced autophagy
appears maladaptive, because inhibition of autophagy via 4-phenyl butyrate (4PBA), HSPA5, or
nonphosphorylatable mutant eIF2a (S51A) overexpression, pepstatin A (PepA), and baﬁlomycin A1
(BAF) prevented AF-associated remodeling and progression in our studies. MHC indicates b-myosin
heavy chain 7.
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inhibitors may precipitate considerable toxicity, as reported for
baﬁlomycin,74 or additional detrimental effects because of
disruption of normal cell physiological characteristics by
inhibition of basal autophagy.15,17,75,76 Application of inhibitors
of autophagy in AF and other chronic conditions thus awaits
development of selective inhibitors targeting excessive autop-
hagy. On the basis of these considerations, 4PBA may serve as
a useful compound to explore the beneﬁts of repression of ER
stress–associated autophagy in the attenuation of AF progres-
sion and improvement of cardioversion outcome in clinical AF.
4PBA may serve as a lead compound for the further develop-
ment of autophagy inhibitors for clinical use.
Limitations
HL-1 atrial cardiomyocytes are derived from mouse atria and
generally show similar features as adult cardiomyocytes.20
Despite potential differences, the ease of conﬁrmation of
speciﬁc molecular pathways conferring tachypaced-induced
remodeling by use of genetic manipulation is an important
advantage of the HL-1 model. Moreover, ﬁndings in the
tachypaced HL-1 atrial cardiomyocyte model have been
conﬁrmed repeatedly in the tachypaced dog model and
clinical human AF.3,8 Therefore, the tachypaced HL-1 model
has merit to identify potential signaling pathways involved in
AF remodeling.
The patient groups differed in terms of medications
prescribed, as expected on the basis of the different disease
causes of each group. For example, patients with AF
frequently received digoxin for rate control, whereas patients
in SR almost never took digoxin. On the other hand, patients
in SR requiring surgery for coronary artery disease, like our
control group, almost always receive b blockers, whereas a
minority of patients with PeAF take them for rate control.
Adjustments for these differences in our overall population
cannot be made because of too few individuals; effects of
drugs may also differ between SR and PeAF populations.
Nevertheless, changes in patient data were similar to those
observed in the in vitro HL-1 atrial cardiomyocyte model and
the in vivo dog model.
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Representative Western blot showing LC3B-I/II, p62, eIF2α-PS51 and mTOR-PS2481 expression in 
normal paced HL-1 cardiomyocytes. Normal pacing does not change the protein expression levels 














































Bright field microscopic images showing the morphology of the HL-1 atrial cardiomyocytes after 
non-pacing (0 h), normal pacing (1 Hz) or tachypacing (6 Hz). No morphological changes were 
observed between the conditions as indicated.  







































Confocal images of multiple tachypaced HL-1 cardiomyocytes, for the period as indicated, (A) 






















Figure S4. LC3B-II levels are not increased during normal pacing after BAF treatment. 
 
 
Representative Western blot showing LC3B-I/II expression in normal paced HL-1 cardiomyocytes 
with and without BAF treatment. BAF doesn’t increase the LC3B-II levels during normal pacing. 














Representative Western blot showing LC3B-I/II expression in normal paced (NP) and 8 h 
tachypaced (TP) HL-1 cardiomyocytes with and without BAF treatment. BAF increases the LC3B-
II levels after 8h tachypacing. 


















Representative Western blot showing eIF2α phosphorylation in normal paced (NP) and 
tachypaced (TP) HL-1 cardiomyocytes. 
 














Top panel: representative Western blot showing HSPA5 and GAPDH expression in normal paced 
(NP) and tachypaced (TP) HL-1 cardiomyocytes. Bottom: quantified data revealing significant 
increase in HSPA5 levels in tachypaced HL-1 cardiomyocytes (N=3). *P≤0.05 vs NP. 










Figures S8. The effect of pharmacological and genetic modulation of autophagy and ER 













(A) Representative CaT (5 sec) of HL-1 cardiomyocytes after normal pacing (NP). HL-1 
cardiomyocytes were pre-treated with the autophagy modulators PepA or BAF, or the chemical 
chaperone 4PBA, followed by normal and measurement of CaT. (B) Quantified CaT of HL-1 
cardiomyocytes pretreated with pepstatin A, bafilomycin A1 or 4PBA and subjected to normal 
pacing, which does not change calcium transients (n/N=60/4). (C) Representative CaT (5 sec) of 
HL-1 cardiomyocytes transfected with empty plasmid (Control), eIF2α wild-type, non-
phosphorylated (S52A) or phospho-mimetic (S52D) mutant and followed by NP. (D) Quantified 
CaT of HL-1 cardiomyocytes transiently transfected with empty plasmid (Control), eIF2α wild-type, 
non-phosphorylated (S52A) or phospho-mimetic (S52D) mutant and subjected to normal pacing, 
















Figure S9. Pharmacological modulation of autophagy in HL-1 cardiomyocytes does not 
change HSPA5 expression. 
 
 
Top panel: representative Western blot showing HSPA5 and GAPDH levels in HL-1 
cardiomyocytes pretreated with various autophagy modulators as indicated. Lower panel: 


























Figure S10. Activators of ER stress and autophagy do not protect against tachypacing-




(A) Representative Western blot showing eIF2α-PS51, p62, LC3B-I/II and GAPDH levels in HL-1 
cardiomyocytes pretreated the ER stress-inducer tunicamycin (TM), the autophagy-inducer 
rapamycin (RP), autophagy inhibitors BAF and pepstatin A and the chemical chaperone 4PBA. 
RP and TM show no protection against tachypacing-induced changes in eIF2α-PS51, p62 or LC3B-
I/II expression. (B) Representative CaT of HL-1 cardiomyocytes after normal pacing (NP) or 
tachypacing (TP), pre-treated with TM or RP. (C) Quantified CaT amplitude of NP and TP HL-1 
cardiomyocytes, each from groups as indicated (n/N=50/3). There is no significant decrease in 
CaT amplitude for either RP or TM at NP, due to the non-toxic concentrations applied. 










Nevertheless, RP and TM did not protect against contractile dysfunction. (D) Representative heart 
wall contractions of Drosophila monitored before TP and after TP with DMSO (Control), TM or RP 
pretreatment. (E) Quantified data showing heart wall contraction rates from groups as indicated. 
RP and TM did not protect against contractile dysfunction. White bars represent normal paced 
(NP in HL-1 cardiomyocytes) or spontaneous heart rate (SR in Drosophila) and black bars 
represent tachypaced HL-1 cardiomyocytes or Drosophila. N=9 to 15 prepupae for each group. 
**P≤0.01, ***P≤0.001 vs control SR, ###P≤0.001  vs control TP 














Atrial tachypacing of dogs results in a borderline significant induction (P=0.06) of HDAC activity, 














Supplemental Video Legends: 
 
Video S1. Time-lapse video shows CaT after 8 hours normal pacing (1Hz) of HL-1 
cardiomyocytes. Images were acquired at 2 ms intervals.  
 
Video S2. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes. 
Images were acquired at 2 ms intervals.  
 
Video S3. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
pretreated with 4PBA. Images were acquired at 2 ms intervals. 
 
Video S4. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
pretreated with 4PBA. Images were acquired at 2 ms intervals.  
 
Video S5. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
transfected with empty plasmid. Images were acquired at 2 ms intervals. 
 
Video S6. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
transfected with empty plasmid. Images were acquired at 2 ms intervals. 
 
Video S7. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
transfected with HSPA5 construct. Images were acquired at 2 ms intervals. 
 
Video S8. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
transfected with HSPA5 construct. Images were acquired at 2 ms intervals. 
 











Video S9. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
pretreated with pepstatin A. Images were acquired at 2 ms intervals.  
 
Video S10. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
pretreated with pepstatin A. Images were acquired at 2 ms intervals.  
 
Video S11. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
pretreated with BAF. Images were acquired at 2 ms intervals. 
 
Video S12. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
pretreated with BAF. Images were acquired at 2 ms intervals. 
 
Video S13. Time-lapse video shows heart wall contractions of a prepupae of a W1118 genetic 
background before tachypacing, and after tachypacing (5Hz, Video S14). 
 
Video S15. Time-lapse video shows heart wall contractions of a prepupae of a W1118 genetic 
background pretreated with BAF before tachypacing, and after tachypacing (5Hz, Video S16). 
 
Video S17. Time-lapse video shows heart wall contractions of a prepupae of a W1118 genetic 
background pretreated with 4PBA before tachypacing, and after tachypacing (5Hz, Video S18). 







































Representative Western blot showing LC3B-I/II, p62, eIF2α-PS51 and mTOR-PS2481 expression in 
normal paced HL-1 cardiomyocytes. Normal pacing does not change the protein expression levels 














































Bright field microscopic images showing the morphology of the HL-1 atrial cardiomyocytes after 
non-pacing (0 h), normal pacing (1 Hz) or tachypacing (6 Hz). No morphological changes were 
observed between the conditions as indicated.  







































Confocal images of multiple tachypaced HL-1 cardiomyocytes, for the period as indicated, (A) 






















Figure S4. LC3B-II levels are not increased during normal pacing after BAF treatment. 
 
 
Representative Western blot showing LC3B-I/II expression in normal paced HL-1 cardiomyocytes 
with and without BAF treatment. BAF doesn’t increase the LC3B-II levels during normal pacing. 














Representative Western blot showing LC3B-I/II expression in normal paced (NP) and 8 h 
tachypaced (TP) HL-1 cardiomyocytes with and without BAF treatment. BAF increases the LC3B-
II levels after 8h tachypacing. 


















Representative Western blot showing eIF2α phosphorylation in normal paced (NP) and 
tachypaced (TP) HL-1 cardiomyocytes. 
 














Top panel: representative Western blot showing HSPA5 and GAPDH expression in normal paced 
(NP) and tachypaced (TP) HL-1 cardiomyocytes. Bottom: quantified data revealing significant 
increase in HSPA5 levels in tachypaced HL-1 cardiomyocytes (N=3). *P≤0.05 vs NP. 










Figures S8. The effect of pharmacological and genetic modulation of autophagy and ER 













(A) Representative CaT (5 sec) of HL-1 cardiomyocytes after normal pacing (NP). HL-1 
cardiomyocytes were pre-treated with the autophagy modulators PepA or BAF, or the chemical 
chaperone 4PBA, followed by normal and measurement of CaT. (B) Quantified CaT of HL-1 
cardiomyocytes pretreated with pepstatin A, bafilomycin A1 or 4PBA and subjected to normal 
pacing, which does not change calcium transients (n/N=60/4). (C) Representative CaT (5 sec) of 
HL-1 cardiomyocytes transfected with empty plasmid (Control), eIF2α wild-type, non-
phosphorylated (S52A) or phospho-mimetic (S52D) mutant and followed by NP. (D) Quantified 
CaT of HL-1 cardiomyocytes transiently transfected with empty plasmid (Control), eIF2α wild-type, 
non-phosphorylated (S52A) or phospho-mimetic (S52D) mutant and subjected to normal pacing, 
















Figure S9. Pharmacological modulation of autophagy in HL-1 cardiomyocytes does not 
change HSPA5 expression. 
 
 
Top panel: representative Western blot showing HSPA5 and GAPDH levels in HL-1 
cardiomyocytes pretreated with various autophagy modulators as indicated. Lower panel: 


























Figure S10. Activators of ER stress and autophagy do not protect against tachypacing-




(A) Representative Western blot showing eIF2α-PS51, p62, LC3B-I/II and GAPDH levels in HL-1 
cardiomyocytes pretreated the ER stress-inducer tunicamycin (TM), the autophagy-inducer 
rapamycin (RP), autophagy inhibitors BAF and pepstatin A and the chemical chaperone 4PBA. 
RP and TM show no protection against tachypacing-induced changes in eIF2α-PS51, p62 or LC3B-
I/II expression. (B) Representative CaT of HL-1 cardiomyocytes after normal pacing (NP) or 
tachypacing (TP), pre-treated with TM or RP. (C) Quantified CaT amplitude of NP and TP HL-1 
cardiomyocytes, each from groups as indicated (n/N=50/3). There is no significant decrease in 
CaT amplitude for either RP or TM at NP, due to the non-toxic concentrations applied. 










Nevertheless, RP and TM did not protect against contractile dysfunction. (D) Representative heart 
wall contractions of Drosophila monitored before TP and after TP with DMSO (Control), TM or RP 
pretreatment. (E) Quantified data showing heart wall contraction rates from groups as indicated. 
RP and TM did not protect against contractile dysfunction. White bars represent normal paced 
(NP in HL-1 cardiomyocytes) or spontaneous heart rate (SR in Drosophila) and black bars 
represent tachypaced HL-1 cardiomyocytes or Drosophila. N=9 to 15 prepupae for each group. 
**P≤0.01, ***P≤0.001 vs control SR, ###P≤0.001  vs control TP 














Atrial tachypacing of dogs results in a borderline significant induction (P=0.06) of HDAC activity, 














Supplemental Video Legends: 
 
Video S1. Time-lapse video shows CaT after 8 hours normal pacing (1Hz) of HL-1 
cardiomyocytes. Images were acquired at 2 ms intervals.  
 
Video S2. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes. 
Images were acquired at 2 ms intervals.  
 
Video S3. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
pretreated with 4PBA. Images were acquired at 2 ms intervals. 
 
Video S4. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
pretreated with 4PBA. Images were acquired at 2 ms intervals.  
 
Video S5. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
transfected with empty plasmid. Images were acquired at 2 ms intervals. 
 
Video S6. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
transfected with empty plasmid. Images were acquired at 2 ms intervals. 
 
Video S7. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
transfected with HSPA5 construct. Images were acquired at 2 ms intervals. 
 
Video S8. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
transfected with HSPA5 construct. Images were acquired at 2 ms intervals. 
 











Video S9. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
pretreated with pepstatin A. Images were acquired at 2 ms intervals.  
 
Video S10. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
pretreated with pepstatin A. Images were acquired at 2 ms intervals.  
 
Video S11. Time-lapse video shows CaT after 8 hours tachypacing (1Hz) of HL-1 cardiomyocytes 
pretreated with BAF. Images were acquired at 2 ms intervals. 
 
Video S12. Time-lapse video shows CaT after 8 hours tachypacing (6Hz) of HL-1 cardiomyocytes 
pretreated with BAF. Images were acquired at 2 ms intervals. 
 
Video S13. Time-lapse video shows heart wall contractions of a prepupae of a W1118 genetic 
background before tachypacing, and after tachypacing (5Hz, Video S14). 
 
Video S15. Time-lapse video shows heart wall contractions of a prepupae of a W1118 genetic 
background pretreated with BAF before tachypacing, and after tachypacing (5Hz, Video S16). 
 
Video S17. Time-lapse video shows heart wall contractions of a prepupae of a W1118 genetic 
background pretreated with 4PBA before tachypacing, and after tachypacing (5Hz, Video S18). 
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